Edition:
United States

Alkermes Plc (ALKS.OQ)

ALKS.OQ on NASDAQ Stock Exchange Global Select Market

54.56USD
17 Jan 2017
Change (% chg)

$-0.90 (-1.62%)
Prev Close
$55.46
Open
$54.96
Day's High
$54.96
Day's Low
$54.06
Volume
311,342
Avg. Vol
396,876
52-wk High
$63.51
52-wk Low
$27.16

ALKS.OQ

Chart for ALKS.OQ

About

Alkermes Public Limited Company is a biopharmaceutical company. The Company is engaged in researching, developing and commercializing, both with partners and on its own, pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of approximately 20 products... (more)

Overall

Beta: 2.14
Market Cap(Mil.): $8,428.28
Shares Outstanding(Mil.): 151.97
Dividend: --
Yield (%): --

Financials

  ALKS.OQ Industry Sector
P/E (TTM): -- 45.90 30.76
EPS (TTM): -1.70 -- --
ROI: -16.05 -1.00 14.82
ROE: -19.93 -0.71 16.24

BRIEF-Alkermes inspiration grants awarded to support people affected by mental health and substance use disorders

* Alkermes inspiration grants(tm) awarded to support people affected by mental health and substance use disorders Source text for Eikon: Further company coverage:

Nov 03 2016

BRIEF-Alkermes Q3 loss per share $0.41

* Alkermes plc qtrly royalty revenue from Bydureon was $11.6 million, compared to $13.0 million for same period in prior year

Nov 02 2016

U.S. RESEARCH ROUNDUP-Alkermes, Chesapeake Energy Corp, Latam Airlines

Oct 21 Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Alkermes, Benchmark Electronics and Copa Holdings on Friday. HIGHLIGHTS * Chesapeake Energy Corp : Nomura raises to neutral from reduce * Latam Airlines : Santander raises to buy from hold * Proofpoint Inc : Piper Jaffray raises target price to $90 from $85; overweight Following is a sum

Oct 21 2016

Alkermes depression drug succeeds in key trial; shares surge

Alkermes Plc's experimental depression drug significantly reduced symptoms in patients suffering from major depressive disorder who were not helped by standard treatments in a pivotal late-stage trial, the company said on Thursday, and its shares surged 47 percent.

Oct 20 2016

UPDATE 2-Alkermes depression drug succeeds in key trial; shares surge

Oct 20 Alkermes Plc's experimental depression drug significantly reduced symptoms in patients suffering from major depressive disorder who were not helped by standard treatments in a pivotal late-stage trial, the company said on Thursday, and its shares surged 47 percent.

Oct 20 2016

Alkermes depression drug meets main goal; shares surge

Oct 20 Alkermes Plc said its lead depression drug met the main goal of a late-stage trial, sending its shares up 48 pct in extended trading.

Oct 20 2016

BRIEF-Alkermes announces topline results from phase 3 study of Alks 5461

* Alkermes announces positive topline results from forward-5 pivotal phase 3 study of alks 5461 for major depressive disorder

Oct 20 2016

BRIEF-Alkermes, certain subsidiaries enter into amendment to amended, restated credit agreement

* Alkermes - On Oct. 12, co, certain other subsidiaries of company entered into an amendment to amended and restated credit agreement - SEC filing

Oct 13 2016

BRIEF-Alkermes submits supplemental new drug application to FDA

* Alkermes submits supplemental new drug application to FDA for two month dosing option of Aristada for treatment of schizophrenia

Aug 08 2016

Competitors

Earnings vs. Estimates